Asia-Pacific Interstitial Cystitis Market, By Severity (Mild To Moderate and Moderate To Severe), Treatment Type (Medication, Bladder Instillations, Botulinum Toxin A, Nerve Stimulation and Surgery), Route Of Administration (Oral, Parenteral, Intravesical, Topical and Others), Mode Of Purchase (Over The Counter and Prescription), Patient Type (Paediatric and Adults), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Retail Sales and Others) - Industry Trends and Forecast to 2029.
Asia-Pacific Interstitial Cystitis Market Analysis and Size
A form of bladder pain condition called interstitial cystitis (IC) causes persistent pain in the bladder and pelvic floor that has no known aetiology. It is known as the female urologic persistent pelvic discomfort syndrome. Feeling the need to urinate immediately and frequently are symptoms. Lower life quality and depression are linked to IC/BPS. Many of those affected also suffer from fibromyalgia and irritable bowel syndrome.
The Asia-Pacific interstitial cystitis market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.1% in the forecast period of 2022 to 2029 and is expected to reach USD 561.95 million by 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customisable to 2019-2014)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
By Severity (Mild To Moderate and Moderate To Severe), Treatment Type (Medication, Bladder Instillations, Botulinum Toxin A, Nerve Stimulation and Surgery), Route Of Administration (Oral, Parenteral, Intravesical, Topical and Others), Mode Of Purchase (Over The Counter and Prescription), Patient Type (Paediatric and Adults), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Retail Sales and Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific
|
|
Market Players Covered
|
Alvogen, Janssen Pharmaceuticals, Inc., Sandoz AG, Sun Pharmaceutical Industries Ltd., Accord Healthcare U.S., Avet Pharmaceuticals Inc., Lannett, Viatris Inc., Pfizer, Inc., Strides Pharma Science Limited, GSK plc. Prestige Consumer Healthcare Inc., Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals, Inc., Apotex Inc., Aurobindo Pharma USA, VistaPharm, Inc., Dr. Reddy’s Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Bayer AG, and Reckitt Benckiser Group PLC, among others.
|
Market Definition
A persistent illness known as interstitial cystitis causes bladder pressure, bladder pain and pelvic pain. Mild discomfort to severe agony is all possible levels of pain. The disorder belongs to a group of illnesses called painful bladder syndrome. Different tests are performed by doctors to diagnose the painful bladder disorder, which include X-rays, urine tests and a bladder wall examination using a cystoscope. It is characterized by pain, pressure, or discomfort perceived to be related to the urinary bladder that lasts more than six months with at least one other urinary symptom, such as frequency or persistent urge. These bladder disorders cause inflammation in the bladder, which is generally called cystitis. Treatment of the disorder depends on the cause of the problem. It may include medication and surgery in severe cases.
Interstitial Cystitis Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
-
INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC)
The disorder known as interstitial cystitis (IC), also known as bladder discomfort syndrome, is chronic or long-lasting and it produces uncomfortable urine symptoms. Individuals with IC may experience varied symptoms. For example, some persons experience little pressure, pain, or discomfort in the pelvic region. Others may battle with severe bladder pain, urinary urgency—the sudden need to urinate—or frequency—the desire to urinate more frequently. One of the main factors influencing the growth rate of the interstitial cystitis market is the increasing prevalence of interstitial cystitis nowadays. Women are particularly affected by this condition. Common side effects include allergies, fibromyalgia and endometriosis. Urinary frequency, urgency and pelvic pain are clinical symptoms of interstitial cystitis, which can occur both during the day and at night.
-
RISE IN HEALTHCARE EXPENDITURE
The cost of healthcare has climbed globally as people's disposable income has increased in different countries. Additionally, government agencies and healthcare providers are taking the initiative by increasing healthcare spending in order to meet population needs.
For instance,
-
As per December 2020, World Health Organization (WHO) report stated that healthcare expenditure was rising in 2018, which was USD 8.3 trillion, which is around 10% of GDP (USD1.080 per citizen) compared to USD 7.6 trillion in 2016. Moreover, health spending grew by 3.9 percent between 2000 and 2017.
Growing healthcare expenditure is also benefiting further economic growth and healthcare sector growth. It is primarily helpful as it significantly affects the development of better and advanced medical products in the market. Thereby surge in healthcare expenditure is expected to act as a driver for the Asia-Pacific interstitial cystitis market.
Opportunities
-
IMPROVING HEALTHCARE SYSTEM
Interstitial cystitis or bladder pain syndrome is a chronic pelvic pain syndrome related to the urinary bladder. It is characterized by pain, pressure, or discomfort perceived to be related to the urinary bladder that lasts more than six months with at least one other urinary symptom, such as frequency or persistent urge. Thus, improvement in one or more symptoms of bladder pain can be particularly effective in improving residual urine and bladder hyperextension.
As a result of rising infectious diseases worldwide, it is required to build a better healthcare system for the diagnosis of various infections in underdeveloped regions. Improving healthcare systems in underdeveloped regions can fuel market growth over the forecast period.
These awareness programs helped people understand the correct treatment at an appropriate time. This increasing awareness allows the consumers to select novel treatments as per age and it is efficacy, which enhances the sales of different types of products. Thus, improving a better healthcare system is expected to act as an opportunity for Asia-Pacific interstitial cystitis market growth in the forecasted period.
Restraints/Challenges
However, the barriers to interstitial cystitis treatment techniques and the high cost of the treatment process in some regions may impede the growth of interstitial cystitis treatment hampering the market growth. Additionally, high competition in medical technology industries and long lead time for the overseas qualification can be challenging factors for the growth of the market.
This interstitial cystitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lung cancer surgery market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you to make an informed market decision to achieve market growth.
Recent Development
- In July 2020, UCB and Ferring Pharmaceuticals Inc. announced they had entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA used for interstitial cystitis.
- In April 2021, Kyorin Pharmaceutical Co., Ltd., a wholly owned subsidiary of KYORIN Holdings, Inc., launched Interstitial cystitis “Zymso Intravesical Solution 50 %.
Asia-Pacific interstitial cystitis market Scope
The Asia-Pacific interstitial cystitis market is segmented into severity, treatment type, route of administration, mode of purchase, patient type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Severity
- Mild To Moderate
- Moderate To Severe
On the basis of severity, the Asia-Pacific interstitial cystitis market is segmented into mild to moderate and moderate to severe.
Treatment Type
- Medications
- Bladder Instillation
- Botulinum Toxin A
- Nerve Stimulation
- Surgery
On the basis of treatment type, the Asia-Pacific interstitial cystitis market is segmented into medications, bladder instillation, botulinum toxin A, nerve stimulation and surgery.
Route of Administration
- Oral
- Parenteral
- Intravesical
- Topical
- Others
On the basis of route of administration, the Asia-Pacific interstitial cystitis market is segmented into oral, parenteral, intravesical, topical and others.
Mode of Purchase
- Over the counter
- Prescription
On the basis of mode of purchase, the Asia-Pacific interstitial cystitis market is segmented into over the counter and prescription.
Patient Type
- Pediatric
- Adults
On the basis of patient type, the Asia-Pacific interstitial cystitis market is segmented into paediatric and adults.
End User
- Hospitals
- Clinics
- Home Healthcare
- Others
On the basis of end user, the Asia-Pacific interstitial cystitis market is segmented into hospitals, clinics, home healthcare and others.
Distribution Channel
- Direct tender
- Retail sales
- Others
On the basis of distribution channels, the Asia-Pacific interstitial cystitis market is segmented into direct tender, retail sales and others.
Interstitial Cystitis Market Regional Analysis/Insights
The interstitial cystitis market is analyzed, and market size insights and trends are provided by country, severity, treatment type, route of administration, mode of purchase, patient type, end user, and distribution channel as referenced above.
Asia-Pacific interstitial cystitis market comprises of the countries China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.
China dominates the Asia-Pacific interstitial cystitis market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the rising need for the verification and validation of interstitial cystitis treatment processes in the region, and rapid research development is boosting the market.
The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Interstitial Cystitis Market Share Analysis
The interstitial cystitis market competitive landscape provides details by the competitors. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the companies focus on the interstitial cystitis market.
Some of the major players operating in the interstitial cystitis market are Alvogen, Janssen Pharmaceuticals, Inc., Sandoz AG, Sun Pharmaceutical Industries Ltd., Accord Healthcare U.S., Avet Pharmaceuticals Inc., Lannett, Viatris Inc., Pfizer, Inc., Strides Pharma Science Limited, GSK plc. Prestige Consumer Healthcare Inc., Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals , Inc., Apotex Inc., Aurobindo Pharma USA, VistaPharm, Inc, Dr. Reddy’s Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Bayer AG, and Reckitt Benckiser Group PLC, among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include the Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.
SKU-